Danielle Brill
Stock Analyst at Truist Securities
(4.12)
# 585
Out of 5,182 analysts
110
Total ratings
47.96%
Success rate
15.88%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintains: Hold | $25 → $29 | $30.99 | -6.42% | 10 | May 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $140 → $155 | $152.25 | +1.81% | 10 | May 7, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $50 → $15 | $7.18 | +108.91% | 1 | Apr 29, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $95 → $102 | $67.39 | +51.36% | 5 | Apr 29, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $68 → $64 | $26.03 | +145.87% | 2 | Apr 14, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $515 → $505 | $295.05 | +71.16% | 4 | Apr 13, 2026 | |
| APGE Apogee Therapeutics | Initiates: Hold | $83 | $83.03 | -0.04% | 1 | Mar 18, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $17 | $11.37 | +49.52% | 1 | Mar 18, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $63 → $110 | $86.71 | +26.86% | 3 | Mar 9, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $68.26 | +21.59% | 8 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $38 | $39.60 | -4.03% | 3 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $60 | $29.00 | +106.90% | 3 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $16 → $22 | $28.94 | -23.98% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $190 | $121.29 | +56.65% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $9.09 | +417.05% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $429.82 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $19.96 | +20.24% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $27.66 | +88.00% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $19.62 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.06 | +46.13% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $10.55 | +70.62% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $19.96 | +651.69% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $193.45 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $782.17 | -22.65% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.40 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $56.44 | -11.41% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.79 | +83.52% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $4.21 | +2,275.30% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $73.69 | - | 9 | Sep 18, 2023 |
Harmony Biosciences Holdings
May 8, 2026
Maintains: Hold
Price Target: $25 → $29
Current: $30.99
Upside: -6.42%
Neurocrine Biosciences
May 7, 2026
Maintains: Buy
Price Target: $140 → $155
Current: $152.25
Upside: +1.81%
Wave Life Sciences
Apr 29, 2026
Maintains: Buy
Price Target: $50 → $15
Current: $7.18
Upside: +108.91%
BridgeBio Pharma
Apr 29, 2026
Maintains: Buy
Price Target: $95 → $102
Current: $67.39
Upside: +51.36%
Maze Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $68 → $64
Current: $26.03
Upside: +145.87%
Alnylam Pharmaceuticals
Apr 13, 2026
Maintains: Buy
Price Target: $515 → $505
Current: $295.05
Upside: +71.16%
Apogee Therapeutics
Mar 18, 2026
Initiates: Hold
Price Target: $83
Current: $83.03
Upside: -0.04%
Climb Bio
Mar 18, 2026
Initiates: Buy
Price Target: $17
Current: $11.37
Upside: +49.52%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $63 → $110
Current: $86.71
Upside: +26.86%
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $68.26
Upside: +21.59%
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $39.60
Upside: -4.03%
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $29.00
Upside: +106.90%
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $28.94
Upside: -23.98%
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $121.29
Upside: +56.65%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $9.09
Upside: +417.05%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $429.82
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $19.96
Upside: +20.24%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $27.66
Upside: +88.00%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $19.62
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.06
Upside: +46.13%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $10.55
Upside: +70.62%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $19.96
Upside: +651.69%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $193.45
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $782.17
Upside: -22.65%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.40
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $56.44
Upside: -11.41%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.79
Upside: +83.52%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $4.21
Upside: +2,275.30%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $73.69
Upside: -